BACKGROUND: Although the influenza vaccine is recommended for patients with end-stage renal disease, little is known about its effectiveness. Observational studies of vaccine effectiveness (VE) are challenging because vaccinated subjects may be healthier than unvaccinated subjects. METHODS: Using US Renal Data System data, we estimated VE for influenza-like illness, influenza/pneumonia hospitalization, and mortality in adult patients undergoing hemodialysis by using a natural experiment created by the year-to-year variation in the match of the influenza vaccine to the circulating virus. We compared vaccinated patients in matched years (1998, 1999, and 2001) with a mismatched year (1997) using Cox proportional hazards models. Ratios of hazard ratios compared vaccinated patients between 2 years and unvaccinated patients between 2 years. We calculated VE as 1 - effect measure. RESULTS: Vaccination rates were less than 50% each year. Conventional analysis comparing vaccinated with unvaccinated patients produced average VE estimates of 13%, 16%, and 30% for influenza-like illness, influenza/pneumonia hospitalization, and mortality, respectively. When restricted to the preinfluenza period, results were even stronger, indicating bias. The pooled ratio of hazard ratios comparing matched seasons with a placebo season resulted in a VE of 0% (95% CI, -3% to 2%) for influenza-like illness, 2% (-2% to 5%) for hospitalization, and 0% (-3% to 3%) for death. CONCLUSIONS: Relative to a mismatched year, we found little evidence of increased VE in subsequent well-matched years, suggesting that the current influenza vaccine strategy may have a smaller effect on morbidity and mortality in the end-stage renal disease population than previously thought. Alternate strategies (eg, high-dose vaccine, adjuvanted vaccine, and multiple doses) should be investigated.
BACKGROUND: Although the influenza vaccine is recommended for patients with end-stage renal disease, little is known about its effectiveness. Observational studies of vaccine effectiveness (VE) are challenging because vaccinated subjects may be healthier than unvaccinated subjects. METHODS: Using US Renal Data System data, we estimated VE for influenza-like illness, influenza/pneumonia hospitalization, and mortality in adult patients undergoing hemodialysis by using a natural experiment created by the year-to-year variation in the match of the influenza vaccine to the circulating virus. We compared vaccinated patients in matched years (1998, 1999, and 2001) with a mismatched year (1997) using Cox proportional hazards models. Ratios of hazard ratios compared vaccinated patients between 2 years and unvaccinated patients between 2 years. We calculated VE as 1 - effect measure. RESULTS: Vaccination rates were less than 50% each year. Conventional analysis comparing vaccinated with unvaccinated patients produced average VE estimates of 13%, 16%, and 30% for influenza-like illness, influenza/pneumonia hospitalization, and mortality, respectively. When restricted to the preinfluenza period, results were even stronger, indicating bias. The pooled ratio of hazard ratios comparing matched seasons with a placebo season resulted in a VE of 0% (95% CI, -3% to 2%) for influenza-like illness, 2% (-2% to 5%) for hospitalization, and 0% (-3% to 3%) for death. CONCLUSIONS: Relative to a mismatched year, we found little evidence of increased VE in subsequent well-matched years, suggesting that the current influenza vaccine strategy may have a smaller effect on morbidity and mortality in the end-stage renal disease population than previously thought. Alternate strategies (eg, high-dose vaccine, adjuvanted vaccine, and multiple doses) should be investigated.
Authors: Kristin L Nichol; James Nordin; John Mullooly; Richard Lask; Kelly Fillbrandt; Marika Iwane Journal: N Engl J Med Date: 2003-04-03 Impact factor: 91.245
Authors: David T Gilbertson; Mark Unruh; A Marshall McBean; Annamaria T Kausz; Jon J Snyder; Allan J Collins Journal: Kidney Int Date: 2003-02 Impact factor: 10.612
Authors: Aurora Pop-Vicas; Momotazur Rahman; Pedro L Gozalo; Stefan Gravenstein; Vincent Mor Journal: J Am Geriatr Soc Date: 2015-08-17 Impact factor: 5.562
Authors: David T Gilbertson; Kenneth J Rothman; Glenn M Chertow; Brian D Bradbury; M Alan Brookhart; Jiannong Liu; Wolfgang C Winkelmayer; Til Stürmer; Keri L Monda; Charles A Herzog; Akhtar Ashfaq; Allan J Collins; James B Wetmore Journal: J Am Soc Nephrol Date: 2019-01-24 Impact factor: 10.121
Authors: J Bradley Layton; Leah J McGrath; John M Sahrmann; Yinjiao Ma; Vikas R Dharnidharka; Caroline O'Neil; David J Weber; Anne M Butler Journal: Vaccine Date: 2020-06-19 Impact factor: 3.641
Authors: Anne M Butler; J Bradley Layton; Vikas R Dharnidharka; John M Sahrmann; Marissa J Seamans; David J Weber; Leah J McGrath Journal: Am J Kidney Dis Date: 2019-08-01 Impact factor: 8.860
Authors: Dana C Miskulin; Daniel E Weiner; Hocine Tighiouart; Eduardo K Lacson; Klemens B Meyer; Taimur Dad; Harold J Manley Journal: Clin J Am Soc Nephrol Date: 2018-10-23 Impact factor: 8.237
Authors: Leah J McGrath; Stephen R Cole; Abhijit V Kshirsagar; David J Weber; Til Stürmer; M Alan Brookhart Journal: Med Care Date: 2013-12 Impact factor: 2.983